We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation and Treatment of Patients With Dermatologic Diseases

This study is currently recruiting participants.
Verified December 21, 2016 by National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
Sponsor:
ClinicalTrials.gov Identifier:
NCT00001506
First Posted: November 4, 1999
Last Update Posted: October 19, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
November 3, 1999
November 4, 1999
October 19, 2017
June 11, 1996
Not Provided
  • Provide clinical material [ Time Frame: Ongoing ]
  • Natural history of selected dermatologic diseases [ Time Frame: Ongoing ]
Not Provided
Complete list of historical versions of study NCT00001506 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Evaluation and Treatment of Patients With Dermatologic Diseases
Evaluation and Treatment of Subjects With Dermatologic Diseases
This is a training, natural history of disease, and screening protocol for the evaluation, treatment and follow-up of patients with dermatologic diseases and systemic diseases with cutaneous manifestations. Patients enrolled in this protocol will be evaluated and treated according to generally available, standard procedures and therapeutic modalities. Samples of blood and skin will be studied by routine and specialized investigative methods to establish these patients' diagnosis, response to treatment, and/or disease progression.

Background

This is a training, natural history of disease, and screening protocol for the evaluation, treatment and follow-up of patients with dermatologic diseases and systemic diseases with cutaneous manifestations. This protocol was developed to allow subject enrollment for teaching purposes and to allow for second opinions regarding relatively complicated patients, and to allow for evaluation of non-invasive tools for the diagnosis and monitoring of cutaneous manifestations. This protocol promotes a critical link between the NCI, CCR Dermatology Branch and the local and national extramural medical communities.

Objectives:

  • To provide clinical material to fulfill the educational mission of the Dermatology Branch.
  • To learn about the natural history of selected dermatologic diseases.

Eligibility:

All subjects regardless of age, gender, or racial/ethnic group with dermatologic disease or systemic disease with cutaneous manifestations.

Design:

Patients enrolled in this protocol will be evaluated and treated according to generally available, standard procedures and therapeutic modalities. Samples of blood and skin will be studied by routine and specialized investigative methods to establish these patients diagnosis, response to treatment, and/or disease progression. Non-invasive tools may be used as part of the examination and assessment of cutaneous manifestations of disease.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
  • Dermatologic Diseases
  • Systemic Diseases With Cutaneous Manifesations
Not Provided
Not Provided
Murray JC, Pollack SV, Pinnell SR. Keloids: a review. J Am Acad Dermatol. 1981 Apr;4(4):461-70. Review.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
500
Not Provided
Not Provided
  • INCLUSION CRITERIA:

Patients of any age, of both genders, and all racial/ethnic groups with dermatologic diseases or systemic diseases with cutaneous manifestations that will help the Branch fulfill the objectives.

Women who are pregnant or lactating, will only undergo tests and procedures, and/or receive medications for which data exists proving minimal risk to the fetus and/or child.

Patients must have a referring physician who will continue to assume primary medical responsibility of care for the patient during and after enrollment in this protocol.

EXCLUSION CRITERIA:

Any participant who, in the investigator s opinion, would be unable to comply with study requirements or for whom participation may pose a greater medical risk.

Sexes Eligible for Study: All
up to 100 Years   (Child, Adult, Senior)
No
Contact: Chrystine V Griffin, R.N. (301) 402-6225 chrysgriffin@nih.gov
Contact: Edward W Cowen, M.D. (301) 480-7196 ec176r@nih.gov
United States
 
 
NCT00001506
960102
96-C-0102
Not Provided
Not Provided
Not Provided
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Edward W Cowen, M.D. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institutes of Health Clinical Center (CC)
December 21, 2016